SCHEMBL25754692

SCHEMBL25754692

CC#CCCCOCCCN(C)CCCN1CCCCC1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 7/20 0.38
HRH3 Q9Y5N1 9/20 0.37
SLC6A2 P23975 3/20 0.35
HRH1 P35367 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
KCNH2 Q12809 2/20 0.35
CHRM2 P08172 1/20 0.35
ADRA2C P18825 1/20 0.35
CACNA1C Q13936 1/20 0.35
SCN5A Q14524 1/20 0.35
CHRM4 P08173 1/20 0.35
HTR2C P28335 1/20 0.35
HTR7 P34969 1/20 0.35
TMEM97 Q5BJF2 1/20 0.35
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754675 0.96 SIGMAR1 (0.37) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754695 0.94 HRH3 (0.40) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754682 0.94 SLC6A3 (0.39) SIGMAR1SLC6A2SLC6A4SLC6A3CYP3A4
SCHEMBL25754676 0.92 HRH3 (0.40) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754672 0.92 HRH3 (0.37) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754686 0.90 HRH3 (0.39) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754668 0.89 SLC6A3 (0.39) SIGMAR1SLC6A2SLC6A4SLC6A3CYP3A4
SCHEMBL25754568 0.87 HRH3 (0.43) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754663 0.86 HRH3 (0.40) SIGMAR1HRH3SLC6A2HRH1SLC6A4
SCHEMBL25754585 0.84 HRH3 (0.48) HRH3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 SIGMAR1 4773/4885HRH3 1596/4885SLC6A2 4723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.